IA2030 Scorecard
—Global
Type to select a Country
Impact Goal 2: Promote Equity
2.2
Provide access to all vaccines
Introduction of new or underutilized vaccines in low- and middle-income countries—Global
200
150
100
50
0
165
2021
57
2022
36
2023
2030 Target
Average of 50 annual introductions
Target: At least
500
cumulative vaccine introductions in low- and middle-income countries by 2030
On track toward 2030 target
Summary Table
| Vaccine introductions | 2021 | 2022 | 2023 |
|---|---|---|---|
| Total | 165 | 57 | 36 |
| Covid | 124 | 0 | 0 |
| DTP Booster 1 | 1 | 2 | 1 |
| DTP Booster 2 | 0 | 4 | 0 |
| DTP Booster 3 | 1 | 4 | 0 |
| HPV | 4 | 10 | 6 |
| Hep A | 0 | 0 | 2 |
| HepB BD | 0 | 2 | 1 |
| HiB | 0 | 0 | 0 |
| IPV2 | 20 | 17 | 15 |
| Influenza | 1 | 1 | 1 |
| MCV2 | 3 | 6 | 2 |
| Malaria | 0 | 0 | 0 |
| MenA | 1 | 2 | 1 |
| Mumps | 0 | 0 | 1 |
| PCV | 5 | 3 | 2 |
| Rotavirus | 4 | 1 | 2 |
| Rubella | 0 | 2 | 0 |
| Typhoid | 1 | 2 | 1 |
| Varicella | 0 | 0 | 1 |
| Yellow Fever | 0 | 1 | 0 |
Definition: Number of introductions of new or under-utilized vaccines in low- and middle-income countries based on most recent World Bank income status classification at the time of reporting. Year of introduction is based on the year the vaccine was first reported, including cases where a vaccine was introduced and was suspended or not administered.
- • Vaccines included in this indicator that are recommended by WHO for use in national immunization schedules in all countries: HepB birth dose, Hib, HPV, IPV2, MCV2, PCV, Rotavirus, Rubella, DTP booster dose 1, DTP booster dose 2, DTP booster dose 3, and COVID-19 (interim recommendation).
- o Only national introductions are included for the indicator reporting based on WHO recommandations
- o Aligning with the Gavi application guidelines, each DTP booster dose is considered an introduction (e.g., two DTP booster vaccine introductions if country introduced two of the three boosters). Both national and subnational introductions are included and it is considered an introduction even if the vaccine was provided outside the WHO recommended age range.
- • Vaccines included in this indicator that are recommended by WHO for use in national immunization schedules in countries in certain geographic region(s), in some high-risk populations, or in immunization programmes with certain characteristics: YF, JE, MenA, multivalent meningitis, HepA, influenza, varicella, mumps, malaria, typhoid, and dengue.
- o MenA vaccine indicator reporting only for countries in the meningitis belt of sub-Saharan Africa. Multivalent meningitis vaccine indicator reporting for countries not in the meningitis belt of sub-Saharan Africa.
- o As part of the indicator revision in spring 2024, reporting on Typhoid vaccine started in 2023 and only includes national introductions for now.
- o Data collection on dengue vaccine from 2024 onwards.
Method of estimation: Step 1) Calculate the indicator value. Count the number of introductions of new or under-utilized vaccines in low- and middle-income countries among WHO Member States.
Limitations: Vaccine may have been introduced earlier than reported but reporting is based on official data from the WHO Member States. Although countries report having introduced select vaccines in national immunization schedules, it does not mean children are vaccinated.
Data source: WHO/UNICEF Joint Reporting Form on Immunization (JRF)
Accessed: undefined
